---
title: "旭辉控股上半年营收 122.8 亿元，上半年净亏损 63.6 亿元。"
description: "旭辉控股上半年营收 122.8 亿元，上半年净亏损 63.6 亿元。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254143674.md"
published_at: "2025-08-22T10:27:41.000Z"
---

# 旭辉控股上半年营收 122.8 亿元，上半年净亏损 63.6 亿元。

旭辉控股上半年营收 122.8 亿元，上半年净亏损 63.6 亿元。

### Related Stocks

- [00884.HK - 旭辉控股集团](https://longbridge.com/zh-CN/quote/00884.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-CN/news/276024005.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-CN/news/275851575.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。